Tectonic Therapeutic Hits Two Trial Milestones With Cash Through 2029

EarningsProduct / Tech
โดย Insider Monkey·US·Read original
Summary · why it matters

Tectonic Therapeutic reported second quarter results on August 6 built around two clinical wins rather than sales, since the clinical-stage biotech has no products on the market. The company completed enrollment for its APEX Phase 2 trial of TX45 in patients with pulmonary hypertension tied to heart failure with preserved ejection fraction in June, bringing in 191 patients across 14 countries, with 137 of them, about 70%, in the sicker CpcPH subgroup with pulmonary vascular resistance above 3 Wood Units. In July an independent data monitoring committee reviewed unblinded safety and efficacy data covering roughly 80% of expected patient exposure and recommended the trial continue without changes, with topline results expected in early Q1 2027. Tectonic also finished dosing all six single-dose cohorts of TX2100 in healthy volunteers in July as part of a Phase 1a trial in hereditary hemorrhagic telangiectasia, with topline results due by the end of Q3 2026 and plans to start a Phase 1b trial in transfusion- or iron-dependent HHT patients and a Phase 2 trial in moderate to severe patients in early 2027, both conditional on favorable data. The company posted a net loss of $22.3 million for the quarter ended June 30, 2026, up from $20 million a year earlier, as R&D spending rose to $18 million from $17.2 million and G&A climbed to $6.2 million from $5.2 million, while cash and cash equivalents fell to $227.1 million from $236.9 million even after raising roughly $11.7 million through an at-the-market stock offering; that runway is projected to last into Q1 2029. Hedge fund ownership rose to 23 funds from 19, while short interest sits at 17.86% of the float.

Impact on stocks 2

Health Care▲ · 1 stocks
Tectonic Therapeutic, Inc.
TECX
▲ PositiveCapitalTechnologyrelevance

Q2 net loss widened to $22.3M on higher R&D and G&A, though cash of $227.1M plus the ATM raise funds the runway into Q1 2029.

Aging Population▲ · 1 stocks

Theme Impact 2

Related news

▲

Amgen Fair Value Target Rises to US$388.03 as Analysts Split on Pipeline Risks

Amgen's updated analyst model lifted its fair value price target to US$388.03 from a prior US$371.93, with the revenue growth assumption rising to 3.50% from 2.93%, the net profit margin assumption moving to 25.15% from 24.84%, the future P/E multiple changing to 25.1x from 24.6x, and the discount rate shifting to 7.96% from 7.70%. The revision reflects a split analyst view, with UBS, Argus, TD Cowen, Scotiabank and Oppenheimer raising their Amgen price targets into a US$420 to US$460 range on the strength of a strong product portfolio, Q2 beats and higher guidance. Wells Fargo and Piper Sandler lifted their targets to US$435, citing external survey work and prescription data they believe support higher long term sales potential for cholesterol and cardiovascular products such as Repatha and Lipfendra. On the bearish side, HSBC downgraded Amgen to Hold and cut its target to US$425 from US$445, saying the stock price now more closely matches its assessment of fair value with limited near term upside, while BMO Capital shifted to a neutral Market Perform stance even with a higher US$450 target, citing ongoing loss of exclusivity headwinds and a need for more clarity on the competitive profile and sales potential of MariTide.
AMGN ▲
Biotech & Genomic Medicine
Simply Wall St·5hRead more →
▲

Edwards Lifesciences Targets $2 Billion TMTT Business by 2030 as CMS Expands TAVR Access

Edwards Lifesciences outlined a structural heart growth plan that targets more than US$2 billion in transcatheter mitral and tricuspid revenue by 2030, anchored by its PASCAL, EVOQUE, and Sapien M3 technologies. The plan sits alongside updated Medicare coverage that could enable 100 to 200 additional U.S. centers to perform TAVR procedures, reinforcing the company's transcatheter ecosystem. Edwards' broader narrative projects $8.5 billion in revenue and $2.2 billion in earnings by 2029, requiring 9.3% yearly revenue growth and an earnings increase of about $1.2 billion from $979.9 million today. Three fair value estimates from the Simply Wall St Community cluster between US$91.47 and US$100.96 per share, against a $100.96 fair value that implies 14% upside to the current price. The company still faces risks around margins, tariffs, and competitive pressure in international markets.
EW ▲
Biotech & Genomic Medicine ▲
Simply Wall St·9hRead more →
▼impact 4

Novartis Shares Plunge 10% as Del-desiran Fails Late-Stage Trial

Novartis shares fell about 10% after the company said its experimental drug del-desiran failed to meet its primary goal in a late-stage trial for myotonic dystrophy type 1, marking its third clinical setback in a week. The earlier failures involved the cardiovascular drug pelacarsen and a pause of eight trials of the cell therapy rap-cel following three patient deaths. The decline erased roughly 24 billion Swiss francs, or about $29.6 billion, in market value and put Novartis on pace for one of its worst trading days in company history. Barclays had estimated peak annual sales of about $3.1 billion for del-desiran and assigned the drug a 60% probability of success after positive mid-stage results, and the failure raises questions about the $12 billion Avidity acquisition that brought the drug into Novartis' pipeline. Management reaffirmed its full-year financial guidance and maintained its target for 5% to 6% compound annual sales growth from 2025 through 2030, while the company reported successful late-stage results for remibrutinib in multiple sclerosis and expects more data later this year.
NOVN.SW ▼
Biotech & Genomic Medicine ▼
CNBC·1dRead more →
© 2026 MarketDXNews